Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-cash Items (2017 - 2025)

Historic Non-cash Items for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $5.2 million.

  • Sutro Biopharma's Non-cash Items fell 1882.79% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 1882.79%. This contributed to the annual value of $5.7 million for FY2023, which is 991.18% up from last year.
  • As of Q3 2025, Sutro Biopharma's Non-cash Items stood at $5.2 million, which was down 1882.79% from $6.6 million recorded in Q2 2025.
  • Sutro Biopharma's Non-cash Items' 5-year high stood at $58.1 million during Q1 2021, with a 5-year trough of $180000.0 in Q4 2023.
  • In the last 5 years, Sutro Biopharma's Non-cash Items had a median value of $5.9 million in 2023 and averaged $11.8 million.
  • As far as peak fluctuations go, Sutro Biopharma's Non-cash Items soared by 289703.9% in 2021, and later crashed by 9287.87% in 2022.
  • Quarter analysis of 5 years shows Sutro Biopharma's Non-cash Items stood at $15.0 million in 2021, then tumbled by 85.38% to $2.2 million in 2022, then tumbled by 91.77% to $180000.0 in 2023, then skyrocketed by 3427.65% to $6.3 million in 2024, then fell by 18.83% to $5.2 million in 2025.
  • Its Non-cash Items stands at $5.2 million for Q3 2025, versus $6.6 million for Q2 2025 and $6.6 million for Q1 2025.